Shares of Aurobindo Pharma were trading in the green and 2% higher on 1 April after the company announced that, through its wholly-owned subsidiaries, it had put four cutting-edge production facilities for Penicillin-G, 6-Amino Penicillanic Acid (6-APA), injectable medicines, and granulation into service.

As to the press statement from the medicine producer, the 6-Amino Penicillanic Acid plant has the capacity to generate 3,600 tonnes yearly, while the Penicillin-G (Pen-G) facility, situated in a Special Economic Zone at Kakinada in Andhra Pradesh, has the ability to create 15,000 tonnes annually and 1.8 lakh tonnes of glucose.

A senior official of the city-based medicine producer previously stated that the Rs 2,400 crore Pen-G factory is anticipated to begin trial production in April and commercial production in a few months. Production will be scaled up during the second quarter of the current fiscal year.

The production facility was granted approval under the Production Linked Incentive (PLI) Program, which aims to encourage domestic production of critical key starting materials (KSMs), drug intermediates, and active pharmaceutical ingredients (APIs) throughout the nation.

The company says the injectable plant can generate 285 million Vials/Ampoules yearly, whereas the Granulated Products unit can produce 13,200 tons annually.

At 3:30 pm, the shares of Aurobindo Pharma closed 1.93% higher at Rs 1,109.75 on NSE.